Device type · OWD
Somatic Gene Mutation Detection System
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
OWD
Pathology
Device class
Class III
FDA decisions since 2015
15
510(k), De Novo and PMA
Adverse event reports
7
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Somatic Gene Mutation Detection System
- Product code
- OWD
- Device class
- Class III
- Review panel
- Pathology
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for OWD
Latest FDA decisions
The 8 newest of 15 since 2015.
P220005 · Decided Sep 29, 2023 · 527 days after receipt
Device type: Somatic gene mutation detection system (OWD) · Laboratory Medicine & Pathology
P210002 · Decided Jun 29, 2023 · 881 days after receipt
Device type: Somatic gene mutation detection system (OWD) · Laboratory Medicine & Pathology
- therascreen KRAS RGQ PCR KITPMA supplement
P110027-S012 · Decided May 28, 2021 · 107 days after receipt · Panel Track
Device type: Somatic gene mutation detection system (OWD) · Laboratory Medicine & Pathology
12 more FDA decisions with a free account
Reports received
7
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
7
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 1 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 1 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 1 | 0 | 0 | 0 |
| Dec 24 | 2 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 1 | 0 | 0 | 0 |
| Apr 25 | 0 | 1 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 2 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 2 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 1 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 2 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- False Positive Result3
- Non Reproducible Results3
- False Negative Result2
3 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions7
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2665-2023 · Started Aug 22, 2023 · Posted by FDA Sep 29, 2023
Reason given: Handbook Revision (Rev13) a dilution step is indicated as an Action when having the Flag SAMPLE_INT_CTRL_FAIL. A dilution of CRC tissue could lead to a false negative result. To remove ambiguity, an alteration must be made to the S the sample result with this flag should be interpreted as invalid
Cause as FDA categorized it: Under Investigation by firm
- therascreen FGFR RGQ RT-PCR kit (US IVD) REF 874721Open, Classified
Z-1650-2022 · Started Jul 20, 2022
Reason given: Increased occurrence rate of false positive results, lead to a false positive sample result that could subsequently be incorrectly reported from the laboratory. A false positive result could lead to the risk of the patient being exposed to an inappropriate or suboptimal anti-cancer treatment and/or unnecessarily...
Cause as FDA categorized it: Under Investigation by firm
Z-1651-2022 · Started Jul 20, 2022
Reason given: Increased occurrence rate of false positive results, lead to a false positive sample result that could subsequently be incorrectly reported from the laboratory. A false positive result could lead to the risk of the patient being exposed to an inappropriate or suboptimal anti-cancer treatment and/or unnecessarily...
Cause as FDA categorized it: Under Investigation by firm
10 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.